Lantheus Holdings Inc
LNTHHealthcare|Drug Manufacturers - Specialty & Generic|USA
$105.64
-0.34 (-0.32%)
DCF (FCF)
$69.11
Tangible Book
$4.10
Graham Number
$22.41
Earnings Power
$25.99
Clinical Trials (86)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT06074510 PYLARIFY® PET/CT or PET/MRI in Men With Favorable Intermediate Risk (FIR) Prostate Cancer | Prostate Cancer | P4 | Active | 274 | Open-label | Piflufolastat F 18 Intravenous Solution [PYLARIFY] |
| NCT05641688 [18F]PI-2620 Phase 3 Histopathological Study | Alzheimer Disease | P3 | Recruiting | 200 | Open-label | [18F]PI-2620 |
| NCT04557501 PSMA PET/CT Guided Intensification of Therapy in Patients at Risk of Advanced Prostate Cancer | Prostate Cancer | P3 | Active | 800 | RCT, Open-label | — |
| NCT03976843 Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer | Prostate Cancer | P2 | Active | 175 | Open-label | 18F-DCFPyL |
| NCT06298916 64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer | Metastatic Sarcoma, Esophageal Cancer | P1P2 | Recruiting | 26 | Open-label | — |
| NCT07357519 Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy) | Relapsed / Refractory Osteosarcoma | P1P2 | Recruiting | 55 | Open-label | LNTH2403 Phase 1 dose, Phase 2; LNTH2403 a single agent recommended phase 2 dose (RP2D). |
| NCT05394259 A Pilot Study to Assess the Clinical Utility of PYLARIFY PET-CT for Detecting Metastasis in Pancreatic Cancer, Hepatocellular Carcinoma and Breast Cancer | Pancreatic Cancer, Breast Cancer | P1 | Recruiting | 36 | Open-label | Piflufolastat F18 |
| NCT07501650 Pembrolizumab Plus Ultrasound-Induced Microbubble Cavitation in Head and Neck Cancer | Head and Neck Cancer, Head and Neck Small Cell Carcinoma | P1 | Recruiting | 6 | Open-label | Pembrolizumab, Definity |
| NCT06790394 Test-retest Study With [18F]FBB in Cardiac Amyloidosis | Cardiac Amyloidosis | P1 | Recruiting | 15 | Open-label | Florbetaben F18 |
| NCT03493516 Prediction of ARrhythmic Events With Positron Emission Tomography II | Sudden Cardiac Arrest, Ischemic Cardiomyopathy | Active | 302 | — | — | |
| NCT07335315 Evaluation of Intraoperative Contrast Enhanced Ultrasound for the Identification of Pituitary Adenoma in Cushing's Disease Compared to Other Pituitary Tumors | Pituitary Adenoma, Cushing Disease | Recruiting | 110 | — | — | |
| NCT04286100 Contrast Specific Echocardiogram Versus Left Ventricular Opacification (LVO) Imaging Settings | Contrast Echocardiography Imaging | Active | 60 | — | — | |
| NCT05416385 Carotid Intraplaque Neovascularization Combined With Stress Echo | Atherosclerosis, Cardiovascular Diseases | Recruiting | 1,500 | — | — | |
| NCT00162331 CARDIOLITE-413: A Study for Patients Who Had a PCI for an Acute MI | Myocardial Infarction | P4 | Completed | 74 | Open-label | Technetium Tc99m Sestamibi |
| NCT00625365 A Prospective, Phase IV, Surveillance Registry Study to Evaluate the Safety of DEFINITY® in Clinical Practice | Cardiovascular Disease | P4 | Completed | 1,060 | Open-label | DEFINITY® |
| NCT00162344 A Study of Stress Heart Imaging in Patients With Diabetes at Risk for Coronary Disease. | Diabetes | P4 | Completed | 205 | Open-label | Technetium Tc99m Sestamibi |
| NCT00401687 DMP115 in Patients With an Ejection Fraction Between 25%-40% to Evaluate the Use of Contrast Echocardiography to Assess Heart Function | Ventricular Ejection Fraction | P4 | Completed | 131 | Open-label | Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension |
| NCT01490892 Quantitative Subharmonic Breast Imaging | Breast Cancer | P4 | Completed | 219 | Open-label | 3D HI and SHI of UCA |
| NCT00162370 A Study of Stress Echocardiography in Post-Menopausal Women at Risk for Coronary Disease | Coronary Artery Disease, Heart Disease | P4 | Completed | 400 | Open-label | Perflutren Lipid Microsphere Injectable Suspension |
| NCT00162357 Post-PCI:Cardiac Imaging in Patients With Diabetes to Detect Coronary Artery Blockages Previously Opened by Angioplasty | Diabetes Mellitus, Type 2, Coronary Restenosis | P4 | Completed | 106 | RCT, Open-label | Technetium Tc99m Sestamibi |
| NCT00918866 A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure | Pulmonary Heart Disease | P4 | Completed | 32 | Open-label | Definity |
| NCT03173716 Real-Time Myocardial Perfusion Echocardiography in the ICU | Myocardial Perfusion Imaging | P4 | Completed | 24 | RCT, Open-label | — |
| NCT03719612 DEF-315 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY | Cardiac Disease | P3 | Completed | 160 | Open-label | DEFINITY® |
| NCT01347710 A Phase 3 Multi-center Study to Assess PET Imaging of Flurpiridaz F 18 Injection in Patients With CAD. | Coronary Artery Disease | P3 | Completed | 795 | Open-label | Flurpiridaz F18, 99mTechnicium (sestamibi or tetrofosmin) |
| NCT07084909 Piflufolastat F 18 PET/CT in Patients With Suspected, or at High Risk for Metastatic ccRCC | Clear Cell Renal Cell Carcinoma | P2P3 | Withdrawn | — | Open-label | piflufolastat F 18 |
| NCT01681524 Open Label Study to Access Flurpiridaz F18 in PET MPI Verses SPECT MPI | Coronary Artery Disease | P3 | Withdrawn | — | Open-label | Flurpiridaz F18 |
| NCT03571672 DEF-314 Better Accuracy in Ejection Fraction (EF) Assessment With DEFINITY | Cardiac Disease | P3 | Completed | 153 | Open-label | DEFINITY |
| NCT00162032 A Study to Evaluate the Use and Safety of CARDIOLITE® in Pediatric Patients With Kawasaki Disease | Kawasaki Disease | P3 | Completed | 445 | Open-label | Sestamibi |
| NCT01020838 Phase III Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid Compared to Histopathology | Alzheimer Disease | P3 | Completed | 218 | Open-label | Florbetaben (BAY94-9172) |
| NCT05247541 Diagnosing Compartment Syndrome With SHAPE vs Elastography | Chronic Exertional Compartment Syndrome | P2P3 | Completed | 15 | Open-label | Definity |
| NCT05184088 Efficacy of [18F]Florbetaben PET for Diagnosis of Cardiac AL Amyloidosis | Cardiac Amyloidosis, AL Amyloidosis | P3 | Completed | 244 | Open-label | [18F]florbetaben |
| NCT02764801 Contrast-enhanced Ultrasound Evaluation of Chemoembolization | Hepatocellular Carcinoma, Chemoembolization, Therapeutic | P3 | Completed | 131 | Open-label | Ultrasound contrast agent (Contrast-enhanced ultrasound) |
| NCT07645326 RISK-ADAPT Protocol in Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) | Metastatic Hormone-sensitive Prostate Cancer (mHSPC) | P2 | Not Yet Recruiting | 108 | Open-label | Androgen Deprivation Therapy (ADT), Androgen Receptor Pathway Inhibitor (ARPI), Docetaxel |
| NCT03243942 Noninvasive, Subharmonic Intra-Cardiac Pressure Measurement | Cardiac Catheterization, Blood Pressure | P2 | Completed | 56 | Open-label | Definity |
| NCT00928304 Phase II Study of Florbetaben (BAY94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid. | Down Syndrome, Amyloid Beta-protein | P2 | Completed | 109 | Open-label | Florbetaben (BAY94-9172) |
| NCT00162045 A Trial to Determine Radiation Exposure to Organs and Assess the Safety of CARDIOLITE® in Pediatric Subjects | Kawasaki Disease | P1P2 | Completed | 79 | Open-label | Technetium Tc99m Sestamibi |
| NCT01384591 Pilot Study of Losartan and N-acetylcysteine as Inhibitors of Muscle Oxidative Stress in Elderly | Aging | P1P2 | Completed | 6 | RCT, Double-blind | N-acetylcysteine, Losartan, Placebo losartan, Placebo N-acetylcysteine |
| NCT05820724 PSMA PET Scan and mpMRI for Prostate Cancer Detection | Prostate Cancer Diagnosis | P2 | Unknown | 100 | RCT, Open-label | 18F- DCFPyl Injection |
| NCT01062178 Efficacy of Ultrasound Contrast Agent to Assess Renal Masses | Renal Cell Carcinoma | P2 | Completed | 167 | Open-label | Definity |
| NCT03907657 Contrast-enhanced Ultrasound as a Screening Tool for Kidney Cancer in Patients With Von-Hippel Lindau | Von-Hippel Lindau, Kidney Disease, Chronic | P2 | Completed | 15 | Open-label | Perflutren lipid microsphere, Sulfur hexafluoride lipid microspheres |
| NCT00162058 A Phase II Study of DMP 115 to Assess Focal Liver Lesions | Liver Disease | P2 | Completed | 80 | Open-label | Peflutren Lipid Microsphere Injectable Suspension |
| NCT06361810 PSMA Therapy and Immunotherapy in Kidney Cancer | Metastatic Renal Cell Carcinoma, Metastatic Clear Cell Renal Cell Carcinoma | P1P2 | Withdrawn | — | Open-label | Pembrolizumab, 177Lu-PNT2002, (F-18)-DCFPyL |
| NCT02483884 PET/CT Imaging Study of the Safety and Diagnostic Performance of [68Ga]RM2 in Patients With Primary Prostate Cancer | Prostate Cancer | P1P2 | Terminated | 30 | Open-label | [68Ga]RM2 |
| NCT00849108 Development of 1-Day Rest/Stress Cardiac PET Perfusion Imaging Protocol of BMS747158 | Ischemia | P2 | Completed | 176 | Open-label | BMS747158 |
| NCT00750282 Phase II Study of Florbetaben (BAY 94-9172) PET Imaging for Detection/Exclusion of Cerebral β-amyloid in Patients With Probable Alzheimer's Disease Compared to Healthy Volunteers | Alzheimer Disease, Amyloid Beta-Protein | P2 | Completed | 422 | Open-label | Florbetaben (BAY94-9172) |
| NCT01085175 Trial to Determine Imaging Parameters of LMI1195 in Heart Failure Patients at Low and High Risk of Defibrillator Firing | Heart Failure | P2 | Withdrawn | — | Open-label | LMI 1195 |
| NCT03196076 Contrast-enhanced Ultrasound for Complex Kidney Lesion Diagnosis in Patients With CKD Extension | Chronic Kidney Diseases, Cystic Kidney Disease | P2 | Completed | 25 | Open-label | Perflutren Lipid microsphere |
| NCT07364071 Strategic Endocrine Therapy and Targeted Radiotherapy for Prostate Cancer | Prostate Adenocarcinoma | P2 | Not Yet Recruiting | 150 | RCT, Open-label | — |
| NCT01153607 Evaluation of the Diagnostic Potential of BAY1006578 in Probable Alzheimers Disease Patients Versus Healthy Volunteers and Radiation Dosimetry of BAY1006578 in Healthy Volunteers | Diagnostic Imaging | P1 | Completed | 24 | Open-label | BAY1006578, BAY1006578, BAY1006578 |
| NCT00707538 A Phase I Study in Healthy Volunteers to Assess Dosimetry and Safety Following Injection of BMS747158 at Stress | Healthy Volunteers | P1 | Completed | 12 | Open-label | BMS747158 |
| NCT01186601 Exploration of Tumor Accumulation of BAY94-9392 in Patients With Cancer | Neoplasms | P1 | Completed | 30 | Open-label | PET tracer (BAY94-9392) |
| NCT02469376 Evaluation of a New Imagingtechnologie for Thrombosis | Abdominal Aortic Aneurysm, Deep Vein Thrombosis | P1 | Terminated | 4 | Open-label | [18F]-GP1 |
| NCT01287845 PET/CT (Positron Emission Tomography/Computed Tomography) Imaging for Safety and Tolerability and Diagnostic Performance of BAY1075553 in Patients With Prostate Cancer and Healthy Volunteers | Diagnostic Imaging | P1 | Completed | 14 | Open-label | BAY1075553, BAY1075553 |
| NCT01205321 PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Biodistribution, Safety and Tolerability and Diagnostic Performance of BAY86-7548 in Patients With Prostate Cancer and Healthy Volunteers | Diagnostic Imaging | P1 | Completed | 19 | RCT, Open-label | Bombesin (68Ga) labeled (BAY86-7548), Bombesin (68Ga) labeled (BAY86-7548) |
| NCT01103310 Radiation Dosimetry, Metabolism, Pharmacokinetics, Safety and Tolerability and PET Imaging With BAY94-9392 in Healthy Volunteers and Patients With Cancer or Inflammation | Diagnostic Imaging, Neoplasms | P1 | Completed | 46 | Open-label | BAY94-9392 |
| NCT01297088 PET/CT (Positron Emission Tomography / Computed Tomography) Investigations With BAY86-9596 (18F) (300 MBq) Following Single Intravenous Administration in Patients With Cancer or Inflammations. | Diagnostic Imaging | P1 | Completed | 24 | Open-label | BAY86-9596 |
| NCT00707499 A Phase I Study in Healthy Volunteers to Assess Safety of BMS747158 | Healthy | P1 | Completed | 13 | Open-label | BMS747158 |
| NCT00930631 Study of [3H] BMS747158 in Healthy Male Subjects | Coronary Artery Disease | P1 | Completed | 7 | Open-label | [3H] BMS747158 |
| NCT02370563 PET Imaging of Intracranial Cancers With 18F-FSPG | Brain Cancer | P1 | Terminated | 26 | Open-label | 18F-FSPG |
| NCT01138111 Florbetaben (BAY94-9172) PET (Positron Emission Tomography) Imaging in MCI (Mild Cognitive Impairment) Patients | Alzheimer Disease, Amyloid Beta-Protein | P1 | Completed | 45 | Open-label | Florbetaben (BAY94-9172) |
| NCT05337774 Imaging [18F]PI-2620 and [18F]Florbetaben in Military Service Members With Blast Related Mild Traumatic Brain Injury | Mild Traumatic Brain Injury | P1 | Terminated | 18 | Open-label | [18F]PI-2620 |
| NCT05187546 Test-retest Study With [18F]PI-2620 in PSP-RS and NDC | Progressive Supranuclear Palsy | P1 | Completed | 15 | Open-label | [18F]-PI2620 |
| NCT04715750 Evaluation of Imaging Characteristics of [18F]PI-2620 PET in AD and PSP Patients Using High and Low Specific Activity | Alzheimer Disease, Progressive Supranuclear Palsy | P1 | Completed | 10 | Open-label | [18F]-PI2620 |
| NCT00891241 A Phase 1 Trial to Determine Dosimetry, Biodistribution and Safety of LMI 1195-101 in Healthy Subjects and Patients With Heart Failure | Heart Failure | P1 | Completed | 12 | Open-label | LMI 1195-101 |
| NCT01089998 PET/CT Imaging for Radiation Dosimetry, Plasma Pharmacokinetics, Safety and Tolerability in Healthy Volunteers and Safety, Tolerability and Diagnostic Performance of BAY86-9596 in Patients With Non-small Cell Lung Cancer, Breast Cancer, Head and Neck Cancer and Patients With Inflammations | Diagnostic Imaging | P1 | Completed | 35 | Open-label | BAY86-9596, BAY86-9596, BAY86-9596, Fludeoxyglucose (18F)-IBA |
| NCT01299649 Retrospective Safety Study to Compare Mortality in Intensive Care Unite (ICU) Patients Undergoing Echocardiography With or Without DEFINITY® | Cardiovascular Disease | Completed | 4,300,000 | — | — | |
| NCT01151566 Can Ultrasound Replace Computed Tomography (CT) Scan in Those Unable to Have Computed Tomography (CT) Contrast Agents | Nephrotoxicity of CT Contrast Agents, CT Scans in Those With Renal Compromise | Completed | 250 | — | — | |
| NCT04093973 Bicycle Exercise Echocardiography to Assess Physiological Significance of Mitral Annular Calcification | Mitral Annulus Calcification | Completed | 40 | — | — | |
| NCT00539045 Diagnostic Utility of Contrast Echocardiography for Detection of LV Thrombi Post ST Elevation Myocardial Infarction | Thrombus, Myocardial Infarction | Completed | 250 | — | — | |
| NCT01005212 Evaluation of Contrast-Enhanced Ultrasound to Detect Endoleaks After Endovascular Aortic Aneurysm Repair | Endoleaks | Completed | 20 | — | Definity | |
| NCT03674255 Echocardiography: Value and Accuracy at REst and STress | Coronary Artery Disease, Ischaemic Heart Disease | By Invite | 23,000 | — | — | |
| NCT04073875 18F-GP1 PET-CT to Detect Bioprosthetic Aortic Valve Thrombosis | Thrombosis Cardiac, Aortic Valve Disease | Completed | 53 | — | — | |
| NCT01165892 Pulmonary MR Angiography and Lower Extremity MR Venous Imaging Using Gadofosveset (Ablavar) | Pulmonary Embolism | Completed | 15 | — | Gadofosveset Triodium | |
| NCT01436773 Identification of Carotid Vasa Vasorum and Correlation With Acute Coronary Events | Coronary Artery Disease | Completed | 66 | — | — | |
| NCT01085162 A Long-term Follow-up Study to Evaluate the Predictive Value of BMS747158 in Patients Suspected of Coronary Artery Disease (CAD) | Coronary Artery Disease (CAD) | Withdrawn | — | — | BMS747158 | |
| NCT01431300 Dose-varied Evaluation of Ablavar-enhanced MR Angiography of the Central Veins of the Chest in Healthy Participants | Healthy | N/A | Completed | 30 | RCT, Double-blind | gadofosveset |
| NCT06033001 Expanded Access Treatment with [Lu-177]-PNT2002 for Adult Patients with Prostate-Specific Membrane Antigen (PSMA)-Positive Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Castration-Resistant Prostatic Cancer | TEMPORARILY_NOT_AVAILABLE | — | — | [Lu-177]-PNT2002 | |
| NCT03297112 Contrast-Enhanced Subharmonic Ultrasound Imaging in Improving Characterization of Adnexal Masses in Patients Undergoing Surgery | Adnexal Mass | Early P1 | Completed | 12 | Open-label | Perflutren Lipid Microspheres |
| NCT05712473 An Observational Registry Assessing the Impact of PYLARIFY® (Piflufolastat F18) PET in Patients With Prostate Cancer | Prostate Cancer | Not Yet Recruiting | 500 | — | — | |
| NCT05160480 A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG | Prostate Cancer, Breast Cancer | By Invite | 9 | — | — | |
| NCT03466255 Early Detection of Cardiovascular Disease | Atheroma, Cardiac Disease | Completed | 610 | — | — | |
| NCT01135316 Prospective Evaluation of the Incidence of NSF in Patients With Kidney Disease Undergoing MR | Nephrogenic Systemic Fibrosis | Completed | 2 | — | Ablavar | |
| NCT02531360 Evaluation of [18F]MNI-815 as a Potential PET Radioligand for Imaging Tau Protein in the Brain of Patients With Tauopathies | Alzheimer's Disease (AD), Progressive Supranuclear Palsy (PSP) | Early P1 | Completed | 7 | Open-label | [18F]MNI-815 (MNI-815) |
| NCT02086695 Early Detection of Broken Hearts in Cancer Patients | Cardiotoxicity | Completed | 43 | — | — | |
| NCT01021865 Effects of Hyperglycemia on Myocardial Perfusion in Humans With and Without Type 2 Diabetes | Coronary Artery Disease, Diabetes Mellitus Type 2 | Completed | 33 | — | Glucagon-Like-Peptide-1/Regadenoson/Perflutren Lipid Microsphere | |
| NCT05326009 A Direct Comparative Study of Tau Tracer in Patients With Alzheimer's Disease | Alzheimer Disease | Unknown | 60 | — | — |